Trials & Approvals
Amylyx’s New ALS Drug Review Impeded as FDA Members Disagreed with Clinical Trial Results
2022-04-04
Ascentage Pharma’s MDM2-p53 Inhibitor Alrizomadlin (APG-115) Granted Rare Pediatric Disease Designation by the US FDA for the Treatment of Neuroblastoma
2022-03-21
Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide & Precision Therapeutics Congress
2022-03-15